Historical Stock Chart
1 Month : From Nov 2019 to Dec 2019
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has been approved in the European Union to treat type-2 diabetes.
The drug maker said that Qtrilmet, a modified-release tablet to improve glycaemic control in adults with type-2 diabetes, was approved by the European Commission, based on data from five Phase 3 trials.
The drug was approved in the U.S. in May under the name Qternmet XR.
Write to Adriano Marchese at firstname.lastname@example.org
(END) Dow Jones Newswires
November 15, 2019 02:26 ET (07:26 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.